PDS Biotechnology Corp
PDSB0.890USD
+0.014+1.57%
收盘 12/19, 16:00（美东）报价延迟15分钟
42.46M总市值
亏损市盈率 TTM
关于 PDS Biotechnology Corp 公司
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp简介
公司代码PDSB
公司名称PDS Biotechnology Corp
上市日期Oct 01, 2015
CEOBedu-Addo (Frank)
员工数量24
证券类型Ordinary Share
年结日Oct 01
公司地址303A College Road East
城市PRINCETON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编08540
电话18002083343
网址https://www.pdsbiotech.com
公司代码PDSB
上市日期Oct 01, 2015
CEOBedu-Addo (Frank)
PDS Biotechnology Corp公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月18日 周二
更新时间: 11月18日 周二
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
3.63%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
其他
92.31%
持股股东
持股股东
占比
The Vanguard Group, Inc.
3.63%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
其他
92.31%
股东类型
持股股东
占比
Investment Advisor
6.46%
Individual Investor
2.69%
Investment Advisor/Hedge Fund
2.14%
Hedge Fund
1.29%
Research Firm
0.65%
Bank and Trust
0.22%
Venture Capital
0.04%
其他
86.51%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
178
7.65M
16.41%
-3.65M
2025Q2
188
9.63M
21.07%
+1.19M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
1.95M
4.18%
+441.12K
+29.21%
Jun 30, 2025
Bedu-Addo (Frank)
690.87K
1.48%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
505.09K
1.08%
+24.12K
+5.01%
Jun 30, 2025
Geode Capital Management, L.L.C.
417.93K
0.9%
-19.95K
-4.56%
Jun 30, 2025
Sykes (Richard)
445.11K
0.95%
--
--
Apr 17, 2025
Citadel Advisors LLC
249.03K
0.53%
+249.03K
--
Jun 30, 2025
Inspirion Wealth Advisors, LLC
344.39K
0.74%
+265.86K
+338.54%
Sep 30, 2025
Squarepoint Capital LLP
97.77K
0.21%
+97.77K
--
Jun 30, 2025
Renaissance Technologies LLC
105.69K
0.23%
+105.69K
--
Jun 30, 2025
William Blair & Company, L.L.C. (Research)
250.00K
0.54%
-7.20K
-2.80%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Invesco NASDAQ Future Gen 200 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
PDS Biotechnology Corp的前五大股东是谁？
PDS Biotechnology Corp 的前五大股东如下：
The Vanguard Group, Inc.持有股份：1.95M，占总股份比例：4.18%。
Bedu-Addo (Frank)持有股份：690.87K，占总股份比例：1.48%。
BlackRock Institutional Trust Company, N.A.持有股份：505.09K，占总股份比例：1.08%。
Geode Capital Management, L.L.C.持有股份：417.93K，占总股份比例：0.90%。
Sykes (Richard)持有股份：445.11K，占总股份比例：0.95%。
The Vanguard Group, Inc.持有股份：1.95M，占总股份比例：4.18%。
Bedu-Addo (Frank)持有股份：690.87K，占总股份比例：1.48%。
BlackRock Institutional Trust Company, N.A.持有股份：505.09K，占总股份比例：1.08%。
Geode Capital Management, L.L.C.持有股份：417.93K，占总股份比例：0.90%。
Sykes (Richard)持有股份：445.11K，占总股份比例：0.95%。
PDS Biotechnology Corp的前三大股东类型是什么？
PDS Biotechnology Corp 的前三大股东类型分别是：
The Vanguard Group, Inc.
Bedu-Addo (Frank)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Bedu-Addo (Frank)
BlackRock Institutional Trust Company, N.A.
有多少机构持有PDS Biotechnology Corp(PDSB)的股份？
截至2025Q3，共有178家机构持有PDS Biotechnology Corp的股份，合计持有的股份价值约为7.65M，占公司总股份的16.41%。与2025Q2相比，机构持股有所增加，增幅为-4.66%。
哪个业务部门对PDS Biotechnology Corp的收入贡献最大？
在--，--业务部门对PDS Biotechnology Corp的收入贡献最大，创收--，占总收入的--%。
